Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NXP900
- Development stage
- Phase 1
- Lead developer
- Nuvectis Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
NXP900 is an oral small molecule inhibitor targeting the SRC family of kinases (SFK), including SRC and YES1. It acts by locking SRC in its inactive "closed" conformation, thereby inhibiting both kinase-dependent catalytic activity and kinase-independent scaffolding functions. This dual inhibition distinguishes it from other multi-targeted kinase inhibitors that only block catalytic activity. NXP900 exhibits high selectivity for SFK members with sub-nanomolar potency and does not inhibit ABL kinase, which may reduce the risk of immunosuppression compared to some other agents. The drug is being developed as an anti-cancer therapy and has shown potent preclinical activity against esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and other advanced solid tumors[2][3][4][5].
- Other names
- eCF506eCF-506eCF 506
02
Targets
YES1 (YES proto-oncogene 1 tyrosine kinase)
Beyond the preview
Go deeper on NXP900.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NXP900.